Company Description
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest.
It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups.
It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care.
The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.
Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
| Country | United States |
| Founded | 1927 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 17,000 |
| CEO | Ivan Tornos |
Contact Details
Address: 345 East Main Street Warsaw, Indiana 46580 United States | |
| Phone | 574 373 3333 |
| Website | zimmerbiomet.com |
Stock Details
| Ticker Symbol | ZBH |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001136869 |
| CUSIP Number | 98956P102 |
| ISIN Number | US98956P1021 |
| Employer ID | 13-4151777 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Ivan Tornos | President, Chief Executive Officer and Chairman of the Board |
| Suketu P. Upadhyay | Chief Financial Officer and Executive Vice President of Finance, Operations and Supply Chain |
| Wilfred van Zuilen | Group President of Europe, Middle East and Africa |
| JehanZeb Noor | Senior Vice President, Chief Strategy, Business Development, Innovation and Transformation Officer |
| Kevin R. Thornal | Group President of Global Businesses and Americas |
| Paul A. Stellato | Vice President, Controller and Chief Accounting Officer |
| Shaun Braun | Senior Vice President and Chief Information and Technology Officer |
| David M. DeMartino | Senior Vice President of Investor Relations |
| Chad F. Phipps J.D. | Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary |
| Angela Main | Senior Vice President, Global Chief Compliance Officer and Associate General Counsel of Asia Pacific |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2026 | ARS | Filing |
| Apr 1, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 12, 2026 | 144 | Filing |
| Feb 20, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | 144 | Filing |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |